Subject(s)
Alopecia Areata , COVID-19 , SARS-CoV-2 , Humans , Alopecia Areata/etiology , COVID-19/epidemiology , COVID-19/complications , FemaleABSTRACT
Both alopecia areata (AA) and vitiligo are distinct, heterogenous, and complex disease entities, characterized by nonscarring scalp terminal hair loss and skin pigment loss, respectively. In AA, inflammatory cell infiltrates are in the deep reticular dermis close to the hair bulb (swarm of bees), whereas in vitiligo the inflammatory infiltrates are in the epidermis and papillary dermis. Immune privilege collapse has been extensively investigated in AA pathogenesis, including the suppression of immunomodulatory factors (e.g., transforming growth factor-ß (TGF-ß), programmed death-ligand 1 (PDL1), interleukin-10 (IL-10), α-melanocyte-stimulating hormone (α-MSH), and macrophage migration inhibitory factor (MIF)) and enhanced expression of the major histocompatibility complex (MHC) throughout hair follicles. However, immune privilege collapse in vitiligo remains less explored. Both AA and vitiligo are autoimmune diseases that share commonalities in pathogenesis, including the involvement of plasmacytoid dendritic cells (and interferon-α (IFN- α) signaling pathways) and cytotoxic CD8+ T lymphocytes (and activated IFN-γ signaling pathways). Blood chemokine C-X-C motif ligand 9 (CXCL9) and CXCL10 are elevated in both diseases. Common factors that contribute to AA and vitiligo include oxidative stress, autophagy, type 2 cytokines, and the Wnt/ß-catenin pathway (e.g., dickkopf 1 (DKK1)). Here, we summarize the commonalities and differences between AA and vitiligo, focusing on their pathogenesis.
Subject(s)
Alopecia Areata , Vitiligo , Alopecia Areata/immunology , Alopecia Areata/pathology , Alopecia Areata/etiology , Alopecia Areata/metabolism , Humans , Vitiligo/immunology , Vitiligo/pathology , Vitiligo/metabolism , Vitiligo/etiology , Animals , Immune Privilege , Cytokines/metabolismABSTRACT
Alopecia areata refers to an autoimmune illness indicated by persistent inflammation. The key requirement for alopecia areata occurrence is the disruption of immune-privileged regions within the hair follicles. Recent research has indicated that neuropeptides play a role in the damage to hair follicles by triggering neurogenic inflammation, stimulating mast cells ambient the follicles, and promoting apoptotic processes in keratinocytes. However, the exact pathogenesis of alopecia areata requires further investigation. Recently, there has been an increasing focus on understanding the mechanisms of immune diseases resulting from the interplay between the nervous and the immune system. Neurogenic inflammation due to neuroimmune disorders of the skin system may disrupt the inflammatory microenvironment of the hair follicle, which plays a crucial part in the progression of alopecia areata.
Subject(s)
Alopecia Areata , Hair Follicle , Neurogenic Inflammation , Alopecia Areata/immunology , Alopecia Areata/etiology , Alopecia Areata/pathology , Humans , Hair Follicle/immunology , Hair Follicle/pathology , Neurogenic Inflammation/immunology , Neurogenic Inflammation/etiology , Neuropeptides/metabolism , Neuropeptides/immunology , Mast Cells/immunology , Keratinocytes/immunology , Keratinocytes/pathology , Apoptosis/immunology , AnimalsABSTRACT
BACKGROUND: Alopecia areata (AA) is an autoimmune condition characterized by sudden and unpredictable hair loss, with a lifetime incidence of 2%. AA can be divided into three categories: patchy alopecia, alopecia totalis, and alopecia universalis. It can affect a person's psychological health and overall quality of life. Elevated C-reactive protein (CRP) levels in the liver may indicate an inflammatory response in autoimmune diseases. Vitamin D, essential for immune system control and skin health, may be related to AA. Hair follicles contain vitamin D receptors, which control immunological responses in the skin. However, no study has found a relationship between CRP and vitamin D in AA patients in our region. SUBJECTS AND METHODS: An analytical cross-sectional study with a case-control design research investigation of 82 AA patients and 81 healthy controls was carried out. Both groups' medical histories were taken. Biochemical analysis was done for both groups as well as the serum vitamin D levels, and CRP. Genetic analysis for CDX2 rs11568820 variant detected by PCR (T-ARMS-PCR) method and vitamin D receptor (VDR) gene expression measured by real-time PCR analysis for both patients and healthy subjects. RESULTS: CRP levels are higher in AA patients, AA patients with G/G genotypes exhibited higher concentrations of CRP when compared to those with A/A and A/G genotypes while patients with A/A genotypes have higher levels of Serum vitamin D as compared to the A/G and G/G genotypes. G allele was more abundant in AA patients. VDR gene expression was lower in AA compared to control and lower in ophiasis compared to localized and multiple patchy AA. An important inverse linear correlation was observed between vitamin D and CRP levels in ophiasis AA. CONCLUSION: CRP concentrations were found to be elevated in AA patients. The considerable accuracy of CRP in the diagnosis of AA is substantiated by a statistically significant al. A noteworthy inverse linear association was observed between serum vitamin D and CRP concentrations in ophiasis AA.
Subject(s)
Alopecia Areata , Vitamin D Deficiency , Humans , Alopecia Areata/etiology , Alopecia Areata/genetics , C-Reactive Protein/metabolism , Cross-Sectional Studies , Quality of Life , Vitamin D Deficiency/diagnosis , Vitamin D Deficiency/complications , Vitamin D , BiomarkersSubject(s)
Alopecia Areata , Tick Bites , Humans , Alopecia Areata/etiology , Tick Bites/complicationsABSTRACT
Obesity and obesity-related conditions today constitute a public health problem worldwide. Obesity is an "epidemic" chronic disorder, which is defined by the WHO as normal or excessive fat accumulation that may impair health. It is also defined for adults as a BMI that is greater than or equal to 30. The most common obesity-related diseases are type 2 diabetes mellitus, cardiovascular diseases, metabolic syndrome, chronic kidney disease, hyperlipidemia, hypertension, nonalcoholic fatty liver disease, and certain types of cancer. It has been also proven that obesity can have a negative effect on hair. It can lead to hair thinning. Patients with obesity can undergo bariatric surgery if they meet the inclusion criteria. The four common types of weight loss surgery include a duodenal switch with biliopancreatic diversion, laparoscopic adjustable gastric banding, Roux-en-Y gastric bypass, and sleeve gastrectomy. Bariatric surgery can affect skin and hair and is associated with telogen effluvium due to weight loss, microelement deficiency, anesthesia, low calorie intake, and low protein intake. Patients who undergo bariatric surgery can experience post-bariatric surgery depression. Hair loss can have a major impact on self-esteem, negatively affecting one's self-image. The purpose of this narrative review is to critically review how obesity, obesity-related diseases, and bariatric surgery affect hair health in general and the hair development cycle, and how they influence hair loss.
Subject(s)
Alopecia Areata , Bariatric Surgery , Diabetes Mellitus, Type 2 , Gastric Bypass , Laparoscopy , Obesity, Morbid , Adult , Humans , Obesity, Morbid/surgery , Diabetes Mellitus, Type 2/etiology , Laparoscopy/methods , Obesity/complications , Obesity/surgery , Bariatric Surgery/adverse effects , Bariatric Surgery/methods , Gastric Bypass/methods , Alopecia Areata/etiology , Alopecia Areata/surgery , HairABSTRACT
This cohort study examines the incidence, prevalence, and risk of alopecia areata after COVID-19.
Subject(s)
Alopecia Areata , COVID-19 , Humans , Alopecia Areata/epidemiology , Alopecia Areata/etiology , COVID-19/complications , Risk FactorsABSTRACT
BACKGROUND: The clinical characteristics and pathomechanism for immune-mediated alopecia following COVID-19 vaccinations are not clearly characterized. OBJECTIVE: We investigated the causality and immune mechanism of COVID-19 vaccines-related alopecia areata (AA). STUDY DESIGN: 27 new-onset of AA patients after COVID-19 vaccinations and 106 vaccines-tolerant individuals were enrolled from multiple medical centers for analysis. RESULTS: The antinuclear antibody, total IgE, granulysin, and PARC/CCL18 as well as peripheral eosinophil count were significantly elevated in the patients with COVID-19 vaccines-related AA compared with those in the tolerant individuals (P = 2.03 × 10-5-0.039). In vitro lymphocyte activation test revealed that granulysin, granzyme B, and IFN-γ released from the T cells of COVID-19 vaccines-related AA patients could be significantly increased by COVID-19 vaccine excipients (polyethylene glycol 2000 and polysorbate 80) or spike protein (P = 0.002-0.04). CONCLUSIONS: Spike protein and excipients of COVID-19 vaccines could trigger T cell-mediated cytotoxicity, which contributes to the pathogenesis of immune-mediated alopecia associated with COVID-19 vaccines.
Subject(s)
Alopecia Areata , COVID-19 , Humans , COVID-19 Vaccines/adverse effects , Spike Glycoprotein, Coronavirus , Alopecia Areata/etiology , Alopecia Areata/pathology , Vaccination/adverse effectsABSTRACT
Coronavirus disease 2019 (COVID-19) has impacted our society in numerous ways. So far (November 2022) around 640 million SARS-CoV-2 infections have been confirmed worldwide. It is known that this disease has a main affection at the cardiopulmonary level, however, it affects almost all the organs and systems of the body, including the skin. Post-COVID-19 syndrome occurs in some patients, leaving significant sequelae that impact their quality of life. Among the most common sequelae are: cough, dyspnea, chronic fatigue, hyposmia and dysosmia. In addition to these, other sequelae not related to respiratory syndrome have been reported, such as hair loss, which has been observed in around 20% of post-COVID-19 patients, this could be attributable to acute telogen effluvium (TE). To date, no study has been conducted to determine the relationship of ET in those who have had COVID-19. Acute ET is defined as diffuse, non-scarring hair loss, usually self-limited, lasting for about 6 months. Within its etiology, severe systemic febrile illness, pregnancy, restrictive diets, severe stress and various drugs have been described. It seriously affects the quality of life of patients and is often associated with loss of confidence and low self-esteem.
La enfermedad por coronavirus 2019 (COVID-19) ha impactado a nuestra sociedad en numerosos aspectos. Hasta el momento (noviembre 2022) se han confirmado alrededor de 640 millones de infecciones por SARS-CoV-2 en el mundo. Se sabe que esta enfermedad tiene afección principal a nivel cardiopulmonar, sin embargo, afecta casi todos los órganos y sistemas del cuerpo, entre ellos, la piel. El síndrome post-COVID-19 se presenta en algunos pacientes dejando secuelas significativas que impactan su calidad de vida. Entre las secuelas más comunes se encuentran: tos, disnea, fatiga crónica, hiposmia y disosmia. Además de estas se han presentado otras secuelas no relacionadas con el síndrome respiratorio, como la caída de pelo, que se ha observado en alrededor del 20% de los pacientes post-COVID-19, esto podría ser atribuible al efluvio telógeno (ET) agudo. Hasta la fecha, no se ha realizado ningún estudio para determinar la relación del ET en quienes han tenido COVID-19. El ET agudo se define como una pérdida de pelo difusa, no cicatrizal, generalmente autolimitada, con una duración de alrededor de 6 meses. Dentro de su etiología, se han descrito la enfermedad febril severa sistémica, el embarazo, las dietas restrictivas, el estrés severo y diversos fármacos. Afecta gravemente la calidad de vida de los pacientes y, a menudo, se asocia con pérdida de confianza y baja autoestima.
Subject(s)
Alopecia Areata , COVID-19 , Humans , Post-Acute COVID-19 Syndrome , Quality of Life , COVID-19/complications , SARS-CoV-2 , Alopecia Areata/etiology , Alopecia/etiology , Alopecia/complications , Acute DiseaseABSTRACT
BACKGROUND: Whilst there are several recognised explanations for persistent telogen-phase hair loss, for a proportion of cases, no clear underlying cause can be identified. These cases have been given the diagnostic label chronic telogen effluvium: a poorly characterised condition where there is legitimate uncertainty as to whether it represents a truly distinct disorder. OBJECTIVE: The aim of this review was to evaluate published cases of purported chronic telogen effluvium and how strongly they support its existence as a distinct disorder. METHODS: We systematically reviewed the literature identified from searching Embase, MEDLINE and Web-of-Science. An additional manual search was performed from the reference lists of publications identified. The review followed PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. The Joanna Briggs Institute's checklists for case reports, case-series, case-control studies and analytical cross-sectional-studies were used to appraise the quality of identified articles. RESULTS: Eighteen studies (comprising five case-series, seven cross-sectional studies, three case-control studies, one case report, one quasi-experimental study and one diagnostic-accuracy study) were included for evaluation, containing 1628 cases. Eleven were rated of good quality. 97.5% of all cases were female. No studies documented that they had excluded all possible causes of telogen hair shedding. Only three studies (encompassing eight cases) featured a prospective follow-up. All eight studies that undertook biopsies reported a normal terminal to vellus hair ratio in the samples analysed. No studies objectively evaluated the influence of hair length or psychological distress/preoccupation on the likelihood of being diagnosed with chronic telogen effluvium. CONCLUSIONS: The lack of a consensual consistent definition for chronic telogen effluvium is a significant limitation. Many cases presently labelled chronic telogen effluvium likely either represent early female pattern hair loss or incipient secondary telogen effluvium owing to an unidentified underlying secondary cause. Where triggering factors have been definitively excluded, hair shedding may represent an alteration in the hair cycle away from normal total asynchronous cycling. Some cases may also represent a preoccupation with normal hair shedding in anxious long-haired individuals.
Subject(s)
Alopecia Areata , Humans , Female , Male , Prospective Studies , Cross-Sectional Studies , Alopecia Areata/etiology , Alopecia/diagnosis , Alopecia/etiology , Alopecia/pathology , Hair/pathologyABSTRACT
Novel coronavirus SARS-CoV-2, designated as COVID-19 by the World Health Organization (WHO) on February 11, 2020, is one of the highly pathogenic β-coronaviruses that infects humans.1 Alopecia areata (AA) is a chronic inflammatory disease with sudden hair loss.2,3 There is strong evidence that AA is a tissue-specific autoimmune disease that develops based on genetic predisposition.4 In several patients, acute or chronic psycho-emotional stress may be causing the initiation and/or progress of AA.5 It is suggested that psychological stress can trigger or exacerbate inflammatory skin diseases through the neuroendocrine system, which is an essential connection between the brain and the skin.6,7 Hair loss has emerged as a frequently noted side effect of infection with COVID-19, and has been observed in many patients who have recovered from a documented COVID-19 illness.8,9.
Subject(s)
Alopecia Areata , COVID-19 , Humans , COVID-19/complications , SARS-CoV-2 , Alopecia Areata/etiology , SkinABSTRACT
For patients diagnosed with breast cancer, alopecia can be a distressing side effect of treatment. Major surgeries, cytotoxic chemotherapy, and endocrine therapy may result in several different types of alopecia. This article reviews the underlying mechanisms, etiology, prevention strategies, and treatment options for chemotherapy-induced alopecia, telogen effluvium, and endocrine-induced alopecia. Here, we aim to provide breast oncologists with a review of the types of hair loss related to cancer therapy and current preventative and treatment options to facilitate informative patient counseling.
Subject(s)
Alopecia Areata , Breast Neoplasms , Humans , Female , Breast Neoplasms/drug therapy , Alopecia/chemically induced , Alopecia Areata/etiologyABSTRACT
Alopecia areata (AA) is an autoimmune cutaneous disorder reported to be related to various immunologic diseases and psychiatric disorders. Some AA patients report the onset of patchy hair loss after surgeries under general anesthesia (GA). However, no large-scale studies have been conducted on the relationship between AA and GA. Thus, we aimed to evaluate whether exposure to GA is associated with an increased risk of AA. In this retrospective study, we analyzed a population exposed to GA. These individuals were compared to unexposed controls, matched by age, sex, income level, and comorbidities (propensity score matching, 1:2 ratio), from the national sample cohort from January 1, 2002, to December 31, 2015. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated for the risk of AA associated with GA using Cox proportional hazard regression. As a result, the risk of AA occurrence was significantly higher in the GA-exposed group after adjusting confounding factors (adjusted HR 1.22, 95% CI 1.07-1.43, P = 0.005). The cumulative incidence of AA was higher in the GA-exposed group (log-rank P = 0.005). The risk of AA increased with GA exposure time. However, the type of surgery and the method of anesthesia did not impact the risk of developing AA. Thus, in conclusion, exposure to GA was associated with a higher risk of developing AA.
Subject(s)
Alopecia Areata , Humans , Alopecia Areata/etiology , Alopecia Areata/complications , Retrospective Studies , Risk Factors , Anesthesia, General/adverse effectsABSTRACT
BACKGROUND: The development of alopecia areata is suggested to be influenced by intestinal permeability and gut dysbiosis. Claudin-3, an essential component of tight junctions which may act as an indicator of intestinal barrier integrity. AIMS: The study's objective was to evaluate the plasma concentration level of Claudin-3 in alopecia areata patients and its relationship to the severity of the condition. PATIENTS AND METHODS: In this case-control study, 50 alopecia areata patients and 30 healthy age and sex controls were involved. An enzyme-linked immunosorbent assay was used to determine the concentration of claudin-3 in the blood. RESULTS: Patients with alopecia areata had significantly higher plasma claudin-3 concentrations than healthy controls [median (interquartile range), 7.73 ng/ml (4.49-33.7) vs. 6.14 ng/ml (4.45-15.6), p < 0.005]. Positive relations were found between claudin-3 and SALT score (r = 0.675 & p-value < 0.001). CONCLUSIONS: Claudin-3, a gut permeability biomarker, is elevated in alopecia areata and correlates with disease severity.
Subject(s)
Alopecia Areata , Claudin-3 , Intestinal Mucosa , Humans , Alopecia Areata/diagnosis , Alopecia Areata/etiology , Alopecia Areata/metabolism , Biomarkers , Case-Control Studies , Claudin-3/blood , Claudin-3/chemistry , Patient Acuity , Intestinal Mucosa/metabolism , Intestinal Mucosa/physiologyABSTRACT
Alopecia areata (AA) involves an aberrant immune attack on the hair follicle (HF), which leads to hair loss. Previous genetic data from our lab pointed to a connection between macroautophagy/autophagy and AA pathogenesis, and GWAS identified STX17, CLEC16A and BCL2L11/BIM as risk factors for AA. Additionally, AA patients have copy number deletions in region spanning the ATG4B gene. To test whether autophagy might contribute to disease pathogenesis in AA, we investigated autophagic activity in C3H/HeJ mouse model. We found that autophagy protein SQSTM1 accumulated in HF of AA mice, while in immune cells from AA skin-draining lymph nodes SQSTM1 was not altered, suggesting that autophagic activity is inhibited in the HF of AA mice. Induction of autophagy with Tat-BECN1 peptide attenuated AA, while treatment with the autophagy blocker chloroquine promoted disease, compared to untreated AA mice. Together, our findings suggest the involvement of impaired autophagy in disease pathogenesis of AA.Abbreviations: AA: alopecia areata; CQ: chloroquine; GWAS: genome-wide association studies; HF: hair follicle; MHC: major histocompatibility complex; SDLN: skin-draining lymph nodes.
Subject(s)
Alopecia Areata , Mice , Animals , Alopecia Areata/etiology , Alopecia Areata/pathology , Genome-Wide Association Study , Mice, Inbred C3H , Autophagy , Disease Models, Animal , Monosaccharide Transport Proteins , Lectins, C-Type/metabolismABSTRACT
Introduction: Alopecia areata is a dermatological disorder characterized by hair loss. The exact cause is still unknown but is linked with an autoimmune disease. No efficient treatment is known though many studies have been conducted, yet the optimal treatment is not known. Methods: The case was treated in the Dermatological Department at Dr. D. Y. Patil Homoeopathic Medical College and Research Centre. A 42-year-old female patient with alopecia areata was treated with individualized homoeopathic medicine (iHOM) between 2nd May 2019 and 16th January 2020. During the follow-up visits, the outcome was assessed. To evaluate whether the changes were due to homoeopathic medicine, an assessment using the Modified Naranjo criteria was performed. Results: Over an observational period of eight-months, positive results from iHOM medicine were seen. This treatment can be used by the physicians in the treatment of alopecia areata as a complementary health practice. Conclusion: Considering the multi-factorial aetiology of alopecia areata, iHOM along with local treatment may be effective in treating alopecia areata.